What question did this study set out to answer?

This research evaluates the cost-effectiveness of the RSVPreF3 vaccine for preventing RSV in COPD patients aged 60-74 in Italy.

February 6, 2026Open Access

Cost-effectiveness of a single dose of the adjuvanted RSVPreF3 vaccine for the prevention of respiratory syncytial virus (RSV) among patients with chronic obstructive pulmonary disease in Italy

Key Points

This research evaluates the cost-effectiveness of the RSVPreF3 vaccine for preventing RSV in COPD patients aged 60-74 in Italy.
Cost-effectiveness analysis conducted over a five-year period
Population included COPD patients aged 60-74
Evaluation of healthcare costs related to RSV disease burden
Single dose of RSVPreF3 vaccine is cost-effective
Potential reduction in RSV-related healthcare costs and disease burden
Benefits observed over a five-year horizon

Abstract

These results indicated that a single dose of adjuvanted RSVPreF3 vaccine in patients with COPD aged 60-74 years in Italy is a cost-effective preventive option that could potentially reduce RSV-related disease burden and costs over five years.

Read Full Paperexternally

Perguntar à IA

Bookmark

View Full Paper